REGN Technical Analysis



As of date:3/28/2024
REGN stock price:962.49
REGN 50 DMA:958.57
REGN 200 DMA:846.24
REGN MACD (200-50):-112.33
REGN RSI:44.35
Extremely
Overbought
Overbought/Oversold RSI Range
RSI Indicator (Relative Strength Index)44.35
Extremely
Oversold

Also see:
REGN Market Cap History
REGN Shares Outstanding History
REGN YTD Return

Quotes delayed 20 minutes

Email EnvelopeFree REGN Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts

MasterCraft Boat Holdings (MCFT) Shares Cross Above 200 DMA
15 hours, 45 minutes ago


Fox Breaks Above 200-Day Moving Average - Bullish for FOXA
15 hours, 45 minutes ago


Vitru Breaks Above 200-Day Moving Average - Bullish for VTRU
15 hours, 45 minutes ago


SASR Makes Bullish Cross Above Critical Moving Average
16 hours, 42 minutes ago


MAG Makes Bullish Cross Above Critical Moving Average
16 hours, 49 minutes ago


Bullish Two Hundred Day Moving Average Cross - CRF
16 hours, 50 minutes ago


DoubleVerify Holdings Breaks Above 200-Day Moving Average - Bullish for DV
16 hours, 58 minutes ago


BIP Crosses Above Key Moving Average Level
17 hours, 5 minutes ago


ZROZ Makes Bullish Cross Above Critical Moving Average
17 hours, 7 minutes ago


Bullish Two Hundred Day Moving Average Cross - HAE
17 hours, 8 minutes ago


AES Shares Cross Above 200 DMA
17 hours, 8 minutes ago


SRE Crosses Above Key Moving Average Level
17 hours, 8 minutes ago


iShares iBonds Dec 2028 Term Muni Bond Getting Very Oversold
17 hours, 8 minutes ago


ZROZ Makes Bullish Cross Above Critical Moving Average
17 hours, 9 minutes ago


FN.CA Makes Bullish Cross Above Critical Moving Average
17 hours, 22 minutes ago


More Technical Analysis News

REGN Technical AnalysisREGN RSI
Regeneron Pharmaceuticals is a biotechnology company. Co.'s products include: EYLEA, which is designed for the treatment of neovascular age-related macular degeneration, diabetic macular edema, macular edema, myopic choroidal neovascularization, diabetic retinopathy, neovascular glaucoma and retinopathy of prematurity; Dupixent, which is designed for the treatment of atopic dermatitis, asthma, rhinosinusitis with nasal polyposis, eosinophilic esophagitis (in adults and adolescents) and prurigo nodularis; and Libtayo, which is designed for the treatment of metastatic or locally advanced first-line non-small cell lung cancer and metastatic or recurrent second-line cervical cancer.

When researching a stock like Regeneron Pharmaceuticals, many investors are the most familiar with Fundamental Analysis — looking at a company's balance sheet, earnings, revenues, and what's happening in that company's underlying business. Investors who use Fundamental Analysis to identify good stocks to buy or sell can also benefit from REGN Technical Analysis to help find a good entry or exit point. Technical Analysis is blind to the fundamentals and looks only at the trading data for REGN stock — the real life supply and demand for the stock over time — and examines that data in different ways.
10 Most Oversold S&P 500 Stocks
10 Most Overbought S&P 500 Stocks

10 ETFs With Stocks Insiders Are Buying
10 ETFs With Most Upside To Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active S&P Call & Put Options
REGN DMAREGN MACD
Video: Technical Analysis


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Regeneron Pharmaceuticals (REGN) is categorized under the Healthcare sector; to help you further research Technical Analysis, below are some other companies in the same sector:

RMD Technical Analysis
RVTY Technical Analysis
STE Technical Analysis
SYK Technical Analysis
TECH Technical Analysis
TFX Technical Analysis
TMO Technical Analysis
UHS Technical Analysis
VRTX Technical Analysis
VTRS Technical Analysis
More Healthcare companies »

 

REGN Technical Analysis | www.TechnicalAnalysisChannel.com | Copyright © 2019 - 2024, All Rights Reserved

Nothing in TechnicalAnalysisChannel.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
X
Wait! Don't leave yet.
Want to receive our latest research absolutely free?


Click the button below for your complimentary copy of Your Early Retirement Portfolio: Dividends Up to 9.5%—Every Month—Forever.

You'll discover the details on 4 stocks and funds that pay you massive dividends as high as 9.5%.